Ahead of what may be China’s first regulatory approval for a cell therapy, the Chinese joint venture between Juno Therapeutics Inc. and WuXi AppTec Inc., JW Therapeutics Co., Ltd, has listed on the Hong Kong Stock Exchange in the latest initial public offering involving a biotech from the mainland.
Shanghai-based JW raised HKD2.33bn ($300m) via the IPO. which the company will use in part to progress several cell therapies...








